Bright Minds Biosciences Inc. (DRUG) return on equity (ROE)

Return on equity · fiscal 2025
-14.9%

Bright Minds Biosciences Inc. (DRUG) earned a return on equity of -14.9% in fiscal 2025 (the year ended September 30, 2025). That is 35.7 percentage points higher than the -50.6% of fiscal 2024. Figures as of 17 Nov 2026, 21:04 UTC, from Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-14.9%
Change on fiscal 2024
+35.7 pts
Highest on record
-14.9%fiscal 2025
Lowest on record
-141.9%fiscal 2022
Fiscal years on record
42022–2025

Figures as of . Statements from Yahoo Finance. Figures, not advice.

Bright Minds Biosciences Inc. return on equity (ROE), in more detail

Across the 4 fiscal years on record (2022–2025), the highest was -14.9% in fiscal 2025 and the lowest -141.9% in fiscal 2022. The fiscal 2025 figure is higher than in every one of the 3 earlier fiscal years on record, whose median is -111.7%.

History · 4 fiscal years

Return on equity by fiscal year

Bright Minds Biosciences Inc. return on equity (ROE), year by year

Bright Minds Biosciences Inc. (DRUG) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-14.9% 35.7 pts up
2024-50.6% 61.1 pts up
2023-111.7% 30.2 pts up
2022-141.9%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

More on DRUG

Bright Minds Biosciences Inc., figure by figure

Bright Minds Biosciences Inc. (DRUG) overview: price, valuation and scorecard

Bright Minds Biosciences Inc. return on equity (ROE): questions and answers

What is Bright Minds Biosciences Inc.'s return on equity?

Bright Minds Biosciences Inc. (DRUG) earned a return on equity of -14.9% in fiscal 2025 (the year ended September 30, 2025). That is 35.7 percentage points higher than the -50.6% of fiscal 2024.

Is Bright Minds Biosciences Inc.'s return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in every one of the 3 earlier fiscal years on record, whose median is -111.7%.

What are the highest and lowest return on equity figures on record for Bright Minds Biosciences Inc.?

Across the 4 fiscal years on record (2022–2025), the highest was -14.9% in fiscal 2025 and the lowest -141.9% in fiscal 2022.

How is Bright Minds Biosciences Inc.'s return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Bright Minds Biosciences Inc. (DRUG) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/DRUG/roe

Underlying data: Yahoo Finance.